7698-98-8

Upstream product

• 106-48-9 4-chloro-phenol 
• 1713-85-5 3-chloro-2-hydroxypropanoic acid 
• 21151-56-4 p-chlorophenoxymethyl chloride 
• 35060-81-2 chlorolactic acid 
• 74953-53-0 N-tert.-butyl 2-hydroxy 3-p-chlorophenoxy propanamide 
• 141921-02-0 2-Acetoxy-2-(4-chloro-phenoxymethyl)-malonic acid diethyl ester 
• 141921-18-8 2-(4-Chloro-phenoxymethyl)-2-hydroxy-malonic acid 

Downstream Products

• 141921-55-3 3-(4-Chloro-phenoxy)-2-hydroxy-propionic acid methyl ester 

Relevant academic research and scientific papers

Synthesis and fungicidal activity of N-2-(3-methoxy-4-propargyloxy) phenethyl amides. Part 3: Stretched and heterocyclic mandelamide oomyceticides

Novel analogues of mandipropamid have been designed and prepared. The synthetic approach to these stretched and heterocyclic mandelamides is outlined. Biological data demonstrate their high efficacy against important plant diseases like tomato and potato

Enantioselective preparation of 2-alkyl-3-aryloxypropionic acids and esters and 3-alkyl-4-chromanones

Lipases provided access to chiral 2-alkyl-3-aryloxypropionic acids that gave chiral 3-alkyl-4-chromanones with high enantioselectivity.

T-Butyl-phenoxy-alkylene esters of benzoic and nicotinic acids, compositions containing same and their antihistaminic method of use

p-Alkyl or cycloalkyl phenoxy alkanols and esters are provided having the structure: STR1 in which: R1 is an alkyl group having from one to six carbon atoms, preferably tertiary, and still more preferably tertiary-butyl; or a bivalent cycloalkylene group condensed with the phenyl group at adjacent ring carbons thereof, such as in indane; R2 is lower alkyl having from one to three carbon atoms or hydrogen; R3 is hydroxyl or an ester group selected from the group consisting of COOR4 and OOCR4 derived from unsubstituted and hydroxy-substituted monocarboxylic acids and COOR5 OOC and OOCR5 COO derived from unsubstituted and hydroxy-substituted dicarboxylic acids, the acids being selected from the group consisting of aliphatic acids, including carbamic acid, having from one to about twelve carbon atoms; cycloaliphatic acids having from three to about twelve carbon atoms; carbocyclic aromatic acids having from six to about twenty carbon atoms; and nitrogen heterocyclic aromatic acids having from five to about twelve carbon atoms, R4 being monovalent aliphatic, cycloaliphatic, aromatic, or nitrogen heterocyclic aromatic, and R5 being divalent aliphatic, cycloaliphatic, aromatic, or nitrogen heterocyclic aromatic, the acids being esterified with aliphatic alcohols having from one to six carbon atoms; and carbonic acid monoalkyl esters, the alkyl having from one to three carbon atoms; and n1, n2 and n3 represent the number of CH2, C(R2)2 and CH2 groups, respectively, and are numbers within the range from 0 to 10; and at least one of n1, n2 and n3 is other than zero. These compounds inhibit abnormal tissue reactivity due to specific allergic hypersensitivity or due to specific irritants by inhibiting the release of chemical mediators that are responsible for the symptoms of allergic diseases, including allergic rhinitis, asthma, hypersensitivity of the skin and of the gastrointestinal canal, and the many symptoms of irritation and inflammation produced by irritants and inflammation-causing substances.

Process for manufacturing phenoxylactic acids, their derivatives and products obtained thereby

The process is for the manufacture of phenoxylactic acids and their derivatives of the general formula: STR1 (in which R1 and R2, identical or different, can represent hydrogen atoms, methyl residues, methoxy groups or halogens; Y re